{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:16:33Z","timestamp":1794071793265,"version":"4.8.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Missouri\/Startup funds"},{"name":"NIH Training Grant T32","award":["GM008396"],"award-info":[{"award-number":["GM008396"]}]},{"name":"MO-LSAMP"},{"name":"NIH-IMSD"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Low-dose computed tomography (LDCT) Non-Small Cell Lung (NSCLC) screening is associated with high false-positive rates, leading to unnecessary expensive and invasive follow ups. There is a need for minimally invasive approaches to improve the accuracy of NSCLC diagnosis. In addition, NSCLC patients harboring sensitizing mutations in epidermal growth factor receptor EGFR (T790M, L578R) are treated with Osimertinib, a potent tyrosine kinase inhibitor (TKI). However, nearly all patients develop TKI resistance. The underlying mechanisms are not fully understood. Plasma extracellular vesicle (EV) and circulating microRNA (miRNA) have been proposed as biomarkers for cancer screening and to inform treatment decisions. However, the identification of highly sensitive and broadly predictive core miRNA signatures remains a challenge. Also, how these systemic and diverse miRNAs impact cancer drug response is not well understood. Using an integrative approach, we examined plasma EV and circulating miRNA isolated from NSCLC patients versus screening controls with a similar risk profile. We found that combining EV (Hsa-miR-184, Let-7b-5p) and circulating (Hsa-miR-22-3p) miRNAs abundance robustly discriminates between NSCLC patients and high-risk cancer-free controls. Further, we found that Hsa-miR-22-3p, Hsa-miR-184, and Let-7b-5p functionally converge on WNT\/\u03b2catenin and mTOR\/AKT signaling axes, known cancer therapy resistance signals. Targeting Hsa-miR-22-3p and Hsa-miR-184 desensitized EGFR-mutated (T790M, L578R) NSCLC cells to Osimertinib. These findings suggest that the expression levels of circulating hsa-miR-22-3p combined with EV hsa-miR-184 and Let-7b-5p levels potentially define a core biomarker signature for improving the accuracy of NSCLC diagnosis. Importantly, these biomarkers have the potential to enable prospective identification of patients who are at risk of responding poorly to Osimertinib alone but likely to benefit from Osimertinib\/AKT blockade combination treatments.<\/jats:p>","DOI":"10.1038\/s41598-022-10598-x","type":"journal-article","created":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T06:02:49Z","timestamp":1650693769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Combining plasma extracellular vesicle Let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction"],"prefix":"10.1038","volume":"12","author":[{"given":"G. P.","family":"Vadla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Daghat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Manjunath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. T.","family":"Kaifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Y.","family":"Chabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,23]]},"reference":[{"key":"10598_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4065\/83.5.584","volume":"83","author":"JR Molina","year":"2008","unstructured":"Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E. & Adjei, A. A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584\u2013594. https:\/\/doi.org\/10.4065\/83.5.584 (2008).","journal-title":"Mayo Clin. Proc."},{"key":"10598_CR2","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.bbcan.2015.08.002","volume":"189\u2013210","author":"H Lemjabbar-Alaoui","year":"1856","unstructured":"Lemjabbar-Alaoui, H., Hassan, O. U., Yang, Y. W. & Buchanan, P. Lung cancer: Biology and treatment options. Biochim. Biophys. Acta. 189\u2013210, 2015. https:\/\/doi.org\/10.1016\/j.bbcan.2015.08.002 (1856).","journal-title":"Biochim. Biophys. Acta."},{"key":"10598_CR3","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis, W. D. et al. The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J. Thorac. Oncol. 10, 1243\u20131260. https:\/\/doi.org\/10.1097\/JTO.0000000000000630 (2015).","journal-title":"J. Thorac. Oncol."},{"key":"10598_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.7326\/M14-2086","volume":"162","author":"PF Pinsky","year":"2015","unstructured":"Pinsky, P. F. et al. Performance of Lung-RADS in the National Lung Screening Trial: A retrospective assessment. Ann. Intern. Med. 162, 485\u2013491. https:\/\/doi.org\/10.7326\/M14-2086 (2015).","journal-title":"Ann. Intern. Med."},{"key":"10598_CR5","doi-asserted-by":"publisher","unstructured":"National Lung Screening Trial Research, T. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395\u2013409 https:\/\/doi.org\/10.1056\/NEJMoa1102873 (2011).","DOI":"10.1056\/NEJMoa1102873"},{"key":"10598_CR6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1097\/JTO.0b013e31828f68d6","volume":"8","author":"A Lopes Pegna","year":"2013","unstructured":"Lopes Pegna, A. et al. Four-year results of low-dose CT screening and nodule management in the ITALUNG trial. J. Thorac. Oncol. 8, 866\u2013875. https:\/\/doi.org\/10.1097\/JTO.0b013e31828f68d6 (2013).","journal-title":"J. Thorac. Oncol."},{"key":"10598_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam, A. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw. Open 2, e192535. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2535 (2019).","journal-title":"JAMA Netw. Open"},{"key":"10598_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch, F. R. et al. Lung cancer: Current therapies and new targeted treatments. Lancet 389, 299\u2013311. https:\/\/doi.org\/10.1016\/S0140-6736(16)30958-8 (2017).","journal-title":"Lancet"},{"key":"10598_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jcma.2013.01.010","volume":"76","author":"YM Chen","year":"2013","unstructured":"Chen, Y. M. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer. J. Chin. Med. Assoc. 76, 249\u2013257. https:\/\/doi.org\/10.1016\/j.jcma.2013.01.010 (2013).","journal-title":"J. Chin. Med. Assoc."},{"key":"10598_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok, T. S. et al. Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947\u2013957. https:\/\/doi.org\/10.1056\/NEJMoa0810699 (2009).","journal-title":"N. Engl. J. Med."},{"key":"10598_CR11","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735\u2013742. https:\/\/doi.org\/10.1016\/S1470-2045(11)70184-X (2011).","journal-title":"Lancet Oncol."},{"key":"10598_CR12","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1158\/1078-0432.CCR-10-2277","volume":"17","author":"ME Arcila","year":"2011","unstructured":"Arcila, M. E. et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin. Cancer Res. 17, 1169\u20131180. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2277 (2011).","journal-title":"Clin. Cancer Res."},{"key":"10598_CR13","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu, H. A. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19, 2240\u20132247. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2246 (2013).","journal-title":"Clin. Cancer Res."},{"key":"10598_CR14","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26. https:\/\/doi.org\/10.1126\/scitranslmed.3002003 (2011).","journal-title":"Sci. Transl. Med."},{"key":"10598_CR15","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","volume":"372","author":"PA Janne","year":"2015","unstructured":"Janne, P. A. et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372, 1689\u20131699. https:\/\/doi.org\/10.1056\/NEJMoa1411817 (2015).","journal-title":"N. Engl. J. Med."},{"key":"10598_CR16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaoncol.2015.1066","volume":"1","author":"HA Yu","year":"2015","unstructured":"Yu, H. A. et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: Emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol. 1, 982\u2013984. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1066 (2015).","journal-title":"JAMA Oncol."},{"key":"10598_CR17","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.21037\/tlcr-20-141","volume":"9","author":"W Fang","year":"2020","unstructured":"Fang, W. et al. PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. Transl. Lung Cancer Res. 9, 1258\u20131267. https:\/\/doi.org\/10.21037\/tlcr-20-141 (2020).","journal-title":"Transl. Lung Cancer Res."},{"key":"10598_CR18","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.21037\/tlcr-20-679","volume":"9","author":"H Chen","year":"2020","unstructured":"Chen, H. et al. Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma. Transl. Lung Cancer Res. 9, 1225\u20131234. https:\/\/doi.org\/10.21037\/tlcr-20-679 (2020).","journal-title":"Transl. Lung Cancer Res."},{"key":"10598_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/JTO.0b013e31820a3a6b","volume":"6","author":"V Ludovini","year":"2011","unstructured":"Ludovini, V. et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 6, 707\u2013715. https:\/\/doi.org\/10.1097\/JTO.0b013e31820a3a6b (2011).","journal-title":"J. Thorac. Oncol."},{"key":"10598_CR20","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.21037\/jtd.2020.03.78","volume":"12","author":"B Gini","year":"2020","unstructured":"Gini, B., Thomas, N. & Blakely, C. M. Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer. J. Thorac. Dis. 12, 2883\u20132895. https:\/\/doi.org\/10.21037\/jtd.2020.03.78 (2020).","journal-title":"J. Thorac. Dis."},{"key":"10598_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.lungcan.2013.11.003","volume":"83","author":"B Li","year":"2014","unstructured":"Li, B. et al. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. Lung Cancer 83, 146\u2013153. https:\/\/doi.org\/10.1016\/j.lungcan.2013.11.003 (2014).","journal-title":"Lung Cancer"},{"key":"10598_CR22","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1515\/hsz-2016-0308","volume":"398","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. & Wang, J. MicroRNAs are important regulators of drug resistance in colorectal cancer. Biol. Chem. 398, 929\u2013938. https:\/\/doi.org\/10.1515\/hsz-2016-0308 (2017).","journal-title":"Biol. Chem."},{"key":"10598_CR23","doi-asserted-by":"publisher","first-page":"114154","DOI":"10.1016\/j.bcp.2020.114154","volume":"189","author":"AS Pal","year":"2020","unstructured":"Pal, A. S., Bains, M., Agredo, A. & Kasinski, A. L. Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer. Biochem. Pharmacol. 189, 114154. https:\/\/doi.org\/10.1016\/j.bcp.2020.114154 (2020).","journal-title":"Biochem. Pharmacol."},{"key":"10598_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.bbrc.2018.11.061","volume":"507","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y., Li, M. & Hu, C. Exosomal transfer of miR-214 mediates gefitinib resistance in non-small cell lung cancer. Biochem. Biophys. Res. Commun. 507, 457\u2013464. https:\/\/doi.org\/10.1016\/j.bbrc.2018.11.061 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10598_CR25","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-y","volume":"75","author":"RC Lee","year":"1993","unstructured":"Lee, R. C., Feinbaum, R. L. & Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843\u2013854. https:\/\/doi.org\/10.1016\/0092-8674(93)90529-y (1993).","journal-title":"Cell"},{"key":"10598_CR26","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/35002607","volume":"403","author":"BJ Reinhart","year":"2000","unstructured":"Reinhart, B. J. et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403, 901\u2013906. https:\/\/doi.org\/10.1038\/35002607 (2000).","journal-title":"Nature"},{"key":"10598_CR27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1126\/science.1064921","volume":"294","author":"M Lagos-Quintana","year":"2001","unstructured":"Lagos-Quintana, M., Rauhut, R., Lendeckel, W. & Tuschl, T. Identification of novel genes coding for small expressed RNAs. Science 294, 853\u2013858. https:\/\/doi.org\/10.1126\/science.1064921 (2001).","journal-title":"Science"},{"key":"10598_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-3-030-26439-0_15","volume":"215","author":"GB Andersen","year":"2020","unstructured":"Andersen, G. B. & Tost, J. Circulating miRNAs as biomarker in cancer. Recent Results Cancer Res. 215, 277\u2013298. https:\/\/doi.org\/10.1007\/978-3-030-26439-0_15 (2020).","journal-title":"Recent Results Cancer Res."},{"key":"10598_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2217\/bmm.14.102","volume":"9","author":"S Khoury","year":"2015","unstructured":"Khoury, S. & Tran, N. Circulating microRNAs: Potential biomarkers for common malignancies. Biomark. Med. 9, 131\u2013151. https:\/\/doi.org\/10.2217\/bmm.14.102 (2015).","journal-title":"Biomark. Med."},{"key":"10598_CR30","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1097\/JTO.0b013e318299ac32","volume":"8","author":"R Cazzoli","year":"2013","unstructured":"Cazzoli, R. et al. microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J. Thorac. Oncol. 8, 1156\u20131162. https:\/\/doi.org\/10.1097\/JTO.0b013e318299ac32 (2013).","journal-title":"J. Thorac. Oncol."},{"key":"10598_CR31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/labinvest.2010.194","volume":"91","author":"J Shen","year":"2011","unstructured":"Shen, J. et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab. Invest. 91, 579\u2013587. https:\/\/doi.org\/10.1038\/labinvest.2010.194 (2011).","journal-title":"Lab. Invest."},{"key":"10598_CR32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.7326\/M13-2771","volume":"160","author":"VA Moyer","year":"2014","unstructured":"Moyer, V. A., US Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 160, 330\u2013338. https:\/\/doi.org\/10.7326\/M13-2771 (2014).","journal-title":"Ann. Intern. Med."},{"key":"10598_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/0969141317727771","volume":"25","author":"PF Pinsky","year":"2018","unstructured":"Pinsky, P. F., Bellinger, C. R. & Miller, D. P. Jr. False-positive screens and lung cancer risk in the National Lung Screening Trial: Implications for shared decision-making. J. Med. Screen. 25, 110\u2013112. https:\/\/doi.org\/10.1177\/0969141317727771 (2018).","journal-title":"J. Med. Screen."},{"key":"10598_CR34","doi-asserted-by":"publisher","first-page":"W244","DOI":"10.1093\/nar\/gkaa467","volume":"48","author":"L Chang","year":"2020","unstructured":"Chang, L., Zhou, G., Soufan, O. & Xia, J. miRNet 2.0: Network-based visual analytics for miRNA functional analysis and systems biology. Nucleic Acids Res. 48, W244\u2013W251. https:\/\/doi.org\/10.1093\/nar\/gkaa467 (2020).","journal-title":"Nucleic Acids Res."},{"key":"10598_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110225","volume":"127","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. Inhibition of Wnt\/beta-catenin pathway reverses multi-drug resistance and EMT in Oct4(+)\/Nanog(+) NSCLC cells. Biomed. Pharmacother. 127, 110225. https:\/\/doi.org\/10.1016\/j.biopha.2020.110225 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"10598_CR36","doi-asserted-by":"publisher","first-page":"djt356","DOI":"10.1093\/jnci\/djt356","volume":"106","author":"DJ Stewart","year":"2014","unstructured":"Stewart, D. J. Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst 106, djt356. https:\/\/doi.org\/10.1093\/jnci\/djt356 (2014).","journal-title":"J Natl Cancer Inst"},{"key":"10598_CR37","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.4049\/jimmunol.1700167","volume":"199","author":"H Shinohara","year":"2017","unstructured":"Shinohara, H. et al. Regulated polarization of tumor-associated macrophages by miR-145 via colorectal cancer-derived extracellular vesicles. J. Immunol. 199, 1505\u20131515. https:\/\/doi.org\/10.4049\/jimmunol.1700167 (2017).","journal-title":"J. Immunol."},{"key":"10598_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12964-018-0229-y","volume":"16","author":"I Popena","year":"2018","unstructured":"Popena, I. et al. Effect of colorectal cancer-derived extracellular vesicles on the immunophenotype and cytokine secretion profile of monocytes and macrophages. Cell Commun. Signal. 16, 17. https:\/\/doi.org\/10.1186\/s12964-018-0229-y (2018).","journal-title":"Cell Commun. Signal."},{"key":"10598_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-3-319-67577-0_6","volume":"1036","author":"TL Whiteside","year":"2017","unstructured":"Whiteside, T. L. Exosomes in cancer: Another mechanism of tumor-induced immune suppression. Adv. Exp. Med. Biol. 1036, 81\u201389. https:\/\/doi.org\/10.1007\/978-3-319-67577-0_6 (2017).","journal-title":"Adv. Exp. Med. Biol."},{"key":"10598_CR40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169\u2013181. https:\/\/doi.org\/10.1038\/nrc2088 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"10598_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000443368","volume":"61","author":"O Tetsu","year":"2016","unstructured":"Tetsu, O., Hangauer, M. J., Phuchareon, J., Eisele, D. W. & McCormick, F. Drug resistance to EGFR inhibitors in lung cancer. Chemotherapy 61, 223\u2013235. https:\/\/doi.org\/10.1159\/000443368 (2016).","journal-title":"Chemotherapy"},{"key":"10598_CR42","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist, L. V. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3327\u20133334. https:\/\/doi.org\/10.1200\/JCO.2012.44.2806 (2013).","journal-title":"J. Clin. Oncol."},{"key":"10598_CR43","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380\u20132388. https:\/\/doi.org\/10.1056\/NEJMoa0909530 (2010).","journal-title":"N. Engl. J. Med."},{"key":"10598_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi, T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11, 121\u2013128. https:\/\/doi.org\/10.1016\/S1470-2045(09)70364-X (2010).","journal-title":"Lancet Oncol"},{"key":"10598_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020073","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73. https:\/\/doi.org\/10.1371\/journal.pmed.0020073 (2005).","journal-title":"PLoS Med."},{"key":"10598_CR46","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","volume":"36","author":"SS Ramalingam","year":"2018","unstructured":"Ramalingam, S. S. et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J. Clin. Oncol. 36, 841\u2013849. https:\/\/doi.org\/10.1200\/JCO.2017.74.7576 (2018).","journal-title":"J. Clin. Oncol."},{"key":"10598_CR47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(17)30480-0","volume":"6","author":"CC Lin","year":"2018","unstructured":"Lin, C. C. et al. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: A genomic study. Lancet Respir. Med. 6, 107\u2013116. https:\/\/doi.org\/10.1016\/S2213-2600(17)30480-0 (2018).","journal-title":"Lancet Respir. Med."},{"key":"10598_CR48","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/PPO.0000000000000147","volume":"21","author":"Z Piotrowska","year":"2015","unstructured":"Piotrowska, Z. & Sequist, L. V. Epidermal growth factor receptor-mutant lung cancer: New drugs, new resistance mechanisms, and future treatment options. Cancer J. 21, 371\u2013377. https:\/\/doi.org\/10.1097\/PPO.0000000000000147 (2015).","journal-title":"Cancer J."},{"key":"10598_CR49","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41467-017-00450-6","volume":"8","author":"K Jacobsen","year":"2017","unstructured":"Jacobsen, K. et al. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nat. Commun. 8, 410. https:\/\/doi.org\/10.1038\/s41467-017-00450-6 (2017).","journal-title":"Nat. Commun."},{"key":"10598_CR50","doi-asserted-by":"publisher","first-page":"7211","DOI":"10.1038\/s41598-020-64215-w","volume":"10","author":"E Priglinger","year":"2020","unstructured":"Priglinger, E. et al. SVF-derived extracellular vesicles carry characteristic miRNAs in lipedema. Sci. Rep. 10, 7211. https:\/\/doi.org\/10.1038\/s41598-020-64215-w (2020).","journal-title":"Sci. Rep."},{"key":"10598_CR51","doi-asserted-by":"publisher","DOI":"10.3791\/51087","author":"M Rames","year":"2014","unstructured":"Rames, M., Yu, Y. & Ren, G. Optimized negative staining: A high-throughput protocol for examining small and asymmetric protein structure by electron microscopy. J. Vis. Exp. https:\/\/doi.org\/10.3791\/51087 (2014).","journal-title":"J. Vis. Exp."},{"key":"10598_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115104","volume":"131","author":"R Kocijan","year":"2020","unstructured":"Kocijan, R. et al. MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis. Bone 131, 115104. https:\/\/doi.org\/10.1016\/j.bone.2019.115104 (2020).","journal-title":"Bone"},{"key":"10598_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167009","volume":"11","author":"S Shore","year":"2016","unstructured":"Shore, S. et al. Small RNA library preparation method for next-generation sequencing using chemical modifications to prevent adapter dimer formation. PLoS ONE 11, e0167009. https:\/\/doi.org\/10.1371\/journal.pone.0167009 (2016).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10598-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10598-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10598-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T20:54:10Z","timestamp":1669323250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10598-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,23]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10598"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10598-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.15.456411","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,23]]},"assertion":[{"value":"23 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Parts of the presented data are under consideration for patent filing (C.Y.C). All other authors declare no conflicts.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6693"}}